Cost Effectiveness of Deep Brain Stimulation for Parkinson’s Disease: A Systematic Review

Akhil Sasidharan, Bhavani Shankara Bagepally () and S Sajith Kumar
Additional contact information
Akhil Sasidharan: ICMR-National Institute of Epidemiology, Health Technology Assessment Resource Centre, ICMR-NIE
Bhavani Shankara Bagepally: ICMR-National Institute of Epidemiology, Health Technology Assessment Resource Centre, ICMR-NIE
S Sajith Kumar: ICMR-National Institute of Epidemiology, Health Technology Assessment Resource Centre, ICMR-NIE

Applied Health Economics and Health Policy, 2024, vol. 22, issue 2, No 6, 192 pages

Abstract: Abstract Background and Objective Deep brain stimulation (DBS) is an established treatment for Parkinson’s disease (PD) in patients with advanced motor symptoms with an inadequate response to pharmacotherapies. Despite its effectiveness, the cost effectiveness of DBS remains a subject of debate. This systematic review aims to update and synthesize evidence on the cost effectiveness of DBS for PD. Methods To identify full economic evaluations that compared the cost effectiveness of DBS with other best medical treatments, a comprehensive search was conducted of the PubMed, Embase, Scopus, and Tufts Cost-Effective Analysis registry databases. The selected papers were systematically reviewed, and the results were summarized. For the quality appraisal, we used the modified economic evaluations bias checklist. The review protocol was a priori registered with PROSPERO, CRD42022345508. Results Sixteen identified cost-utility analyses that reported 19 comparisons on the use of DBS for PD were systematically reviewed. The studies were primarily conducted in high-income countries and employed Markov models. The costs considered were direct costs: surgical expenses, calibration, pulse generator replacement, and annual drug expenses. The majority of studies used country-specific thresholds. Fourteen comparisons from 12 studies reported on the cost effectiveness of DBS compared to best medical treatments. Eleven comparisons reported DBS as cost effective based on incremental cost-utility ratio results. Conclusions The cost effectiveness of DBS for PD varies by time horizon, costs considered, threshold utilized, and stage of PD progression. Standardizing approaches and comparing DBS with other treatments are needed for future research on effective PD management.

Date: 2024
References: Add references at CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40258-023-00848-y Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:aphecp:v:22:y:2024:i:2:d:10.1007_s40258-023-00848-y

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40258

DOI: 10.1007/s40258-023-00848-y

Access Statistics for this article

Applied Health Economics and Health Policy is currently edited by Timothy Wrightson

More articles in Applied Health Economics and Health Policy from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().